Phase I Study of BMS-599626 in Patients With Advanced Solid Malignancies, Including Malignancies That Express HER2 at the Maximum Tolerated Dose and/or Recommended Phase II Dose

Inclusion Criteria:

- Diagnosis of metastatic cancer that has progressed on currently available therapies;

- At least 3 month life expectancy;

- Primary cancer must be solid (non-hematologic);

- Adequate bone marrow, liver & kidney function;

- Negative pregnancy test.

Exclusion Criteria:

- Serious, uncontrolled medical disorder;

- Individuals not willing or able to use an acceptable method to avoid pregnancy for
the entire study period and for at least 3 months after the study;

- Pregnant or breastfeeding women;

- Patients with known brain metastasis;

- Uncontrolled or significant cardiovascular disease;

- Anticancer therapy within 2-6 weeks prior to study drug (depending on the therapy)